← Back to Clinical Trials
Recruiting NCT04383808

NCT04383808 Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04383808
Status Recruiting
Phase
Sponsor Stanford University
Condition Brain Disease
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-04-01
Primary Completion 2027-03-31

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Injected radiotracer with PET InsertPre-injected group with PET insert

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-04-01 with a primary completion date of 2027-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET/MRI system using a common radiopharmaceutical.

Eligibility Criteria

Inclusion Criteria: 1. Whole body radiation dose within the last year of less than 5000 mrem 2. Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved 3. Subjects will be at least 21 years of age 4. Subject provides written informed consent 5. Subject is deemed healthy by the PI by via self-reported questionnaire Exclusion Criteria: 1. For patients who will be receiving a tracer injection, no known allergy to the imaging agents 2. Participant has a history of or current diagnosis of cancer 3. Participant is pregnant or nursing 4. Metallic implants (contraindicated for MRI)

Contact & Investigator

Central Contact

Paul Newswanger

✉ pdn@stanford.edu

📞 (650) 736-1349

Frequently Asked Questions

Who can join the NCT04383808 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Brain Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04383808 currently recruiting?

Yes, NCT04383808 is actively recruiting participants. Contact the research team at pdn@stanford.edu for enrollment information.

Where is the NCT04383808 trial being conducted?

This trial is being conducted at Palo Alto, United States.

Who is sponsoring the NCT04383808 clinical trial?

NCT04383808 is sponsored by Stanford University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology